We are excited to announce that our manuscript “Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria” was recently published in the esteemed medical journal, the Journal of Thoracic Oncology (JTO). The article, which was co-authored by members of the Expanded Eligibility working group of the LUNGevity Scientific and Clinical Roundtable initiative, provides recommendations for expanding overly restrictive eligibility criteria to enable more lung cancer patients, particularly those with brain metastases, history of previous malignancies, and reduced performance status, to participate in clinical trials. This is an important step forward, as previous exclusion of these three conditions could have been excluding as many as 50% of lung cancer patients from trials. There is still work to be done. We will continue to seek avenues to discuss, disseminate, and present our recommendations in order to ensure they are acted upon and trial sponsors begin incorporating the findings into new trial design. We are very excited by this milestone and hope that you are too! Learn more about this and LUNGevity’s many other programs and initiatives by visiting our website, www.LUNGevity.org, or read about our recent accomplishments in our Spring newsletter. Best regards, Andrea Ferris |